Japanese Encephalitis News and Research

RSS
Japanese encephalitis (previously known as Japanese B encephalitis to distinguish it from von Economo's A encephalitis) is a disease caused by the mosquito-borne Japanese encephalitis virus. The Japanese encephalitis virus is a virus from the family Flaviviridae. Domestic pigs and wild birds are reservoirs of the virus; transmission to humans may cause severe symptoms. One of the most important vectors of this disease is the mosquito ''Culex tritaeniorhynchus''. This disease is most prevalent in Southeast Asia and the Far East.
Rising temperature induces key changes in dengue virus

Rising temperature induces key changes in dengue virus

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

New research focuses on rapid identification of disease outbreaks

New research focuses on rapid identification of disease outbreaks

Sanofi Pasteur’s IMOJEV vaccine against Japanese encephalitis is now available in Australia

Sanofi Pasteur’s IMOJEV vaccine against Japanese encephalitis is now available in Australia

BMJ examines emergence of China as 'major new player' in global vaccine production

BMJ examines emergence of China as 'major new player' in global vaccine production

Wellcome Trust awards University of Maryland $4M to accelerate development of conjugate NTS vaccine

Wellcome Trust awards University of Maryland $4M to accelerate development of conjugate NTS vaccine

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac first quarter sales increase 30.3% to $6.0M

Computer model can predict malaria epidemics in India

Computer model can predict malaria epidemics in India

USPTO issues two patents on 'Novel Shigella protein antigens and methods' to IVI

USPTO issues two patents on 'Novel Shigella protein antigens and methods' to IVI

Experimental sublingual vaccine shows promise against influenza infection

Experimental sublingual vaccine shows promise against influenza infection

Inviragen commences DENVax Phase 2 trial for dengue

Inviragen commences DENVax Phase 2 trial for dengue

New creative uses of DNA 'barcoding'

New creative uses of DNA 'barcoding'

IVI receives WHO prequalification for new oral cholera vaccine

IVI receives WHO prequalification for new oral cholera vaccine

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Inviragen commences INV21 Phase 1 trial against Hand, Foot and Mouth Disease

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech announces the pricing for ROTAVAC vaccine

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac reports fourth quarter net sales of $9.1 million

Sinovac reports fourth quarter net sales of $9.1 million

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

ITMNs can reduce Japanese Encephalitis transmission to humans

ITMNs can reduce Japanese Encephalitis transmission to humans